Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof

Abstract

An isolated, pure homogeneous population of mammalian astrocyte retricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided.

1 . A pure homogeneous population of mammalian astrocyte restricted precursor cells, said population of mammalian astrocyte restricted precursor cells being CD44 immunoreactive and generating astrocytes but not oligodendrocytes.  
     
     
         2 . A method for isolating the pure homogeneous population of mammalian astrocyte-restricted precursor cells of  claim 1  comprising isolating from a source of neural tissue or cells a population of cells exhibiting CD44 immunoreactivity.  
     
     
         3 . A pharmaceutical composition comprising the pure homogeneous population of astrocyte restricted precursor cells of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         4 . The pharmaceutical composition of  claim 3  wherein the pharmaceutically acceptable carrier is an implant seeded or coated with the astrocyte restricted precursor cells.  
     
     
         5 . A method for treating damaged neural cells comprising administering to the damaged neural cells the pharmaceutical composition of  claim 3 .  
     
     
         6 . The method of  claim 5  wherein the pharmaceutical composition is administered to the damaged neural cells by direct injection to the damaged neural cells.  
     
     
         7 . The method of  claim 5  wherein the pharmaceutical composition comprises an implant seeded or coated with the astrocyte restricted precursor cells.  
     
     
         8 . The method of  claim 7  wherein the pharmaceutical composition is implanted at or near a site of damaged neural cells.  
     
     
         9 . The method of  claim 5  wherein administering the pharmaceutical composition to the damaged neural cells enhances myelination of the damaged neural cells.  
     
     
         10 . The method of  claim 5  wherein administering the pharmaceutical composition to the damaged neural cells reduces scar formation in the damaged neural cells.